Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank13
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-70.30M
↓ 108% vs avg
Percentile
P13
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-33.77M
Historical baseline
PeriodValueYoY Change
2025$-70.30M+3.9%
2024$-73.19M-19.5%
2023$-61.27M-91.0%
2022$-32.08M-67.6%
2021$-19.13M-124.3%
2020$-8.53M+61.0%
2019$-21.88M-149.3%
2018$-8.78M+0.1%
2017$-8.79M-